Congress quietly expands Medicaid for mental health—and pharma stocks rise
H.R. 4745 — Medicaid Bump Act · Filed by Paul Tonko (D-NY) · 3 cosponsors · Introduced Jul 23, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
The Medicaid Bump Act increases the federal government's share of costs for behavioral health services (mental health and substance use treatment) from the standard rate to 90% for any spending above 2019 baseline levels. States must use the extra federal money to supplement (not replace) existing behavioral health funding and invest in provider capacity, efficiency, and quality—including higher payment rates and staff retention. HHS must issue guidance within 180 days and report annually on state behavioral health spending and payment rates.
Why we flagged it
The bill's core mechanism is a targeted increase in federal matching funds for mental health and substance use services under Medicaid, with explicit guardrails against cost-shifting and requirements for service improvement.
What the text implies
- The 2019 baseline creates a historical anchor that may disadvantage states that already invested heavily in behavioral health pre-pandemic, as they receive smaller incremental federal support relative to states that underinvested.
- The 90% federal match for incremental spending is significantly higher than standard Medicaid rates (typically 50–75%), creating a strong financial incentive for states to expand behavioral health—but only if they can sustain matching funds after the incentive period ends.
The full analysis lists 4 implications of this text.
Who stands to gain
behavioral health service providers; mental health and substance use treatment facilities; pharmaceutical companies with behavioral health medications